ADVANTAME. Not less than 97.0% and not more than 102.0% on the anhydrous basis. Sweetener, flavour enhancer

Similar documents
ADVANTAME (TENTATIVE)

BRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].

INDIGOTINE. Disodium 3,3'-dioxo-[delta 2,2' -biindoline]-5,5'-disulfonate (principal component) (principal component)

Dissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.

ASPARTAME. Not less than 98% and not more than 102% on the dried basis. White, odourless, crystalline powder, having a strong sweet taste

ARTEMETHER AND LUMEFANTRINE ORAL SUSPENSION:Final text for addition to The International Pharmacopoeia (November 2008)

ARTEMETHER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008)

LUMEFANTRINUM LUMEFANTRINE

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD

ANALYTICAL METHOD PROCEDURES

Egualen Sodium Granules

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

Ondansetron Hydrochloride Tablets

CYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE

NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)

EFAVIRENZ Final text for addition to The International Pharmacopoeia

Revision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance

Should you have any questions, please contact Mary P. Koleck, Ph.D., Scientific Liaison ( or

POLYVINYL ALCOHOL. SYNONYMS Vinyl alcohol polymer, PVOH, INS No DEFINITION DESCRIPTION FUNCTIONAL USES CHARACTERISTICS

Revision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance

Additionally, minor editorial changes have been made to update the monograph to current USP style.

USP 36 Official Monographs / Metformin carding the first 3 ml of filtrate. Transfer 25 ml of the Analysis

USP 35 Official Monographs / Oxaliplatin 4143 DEFINITION

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

H 3 CO H 3 CO S CH 3

CIPAC. CIPAC Free relevant impurities methods:

Revision Bulletin Official April 1, 2014 Alprazolam 1

TERTIARY BUTYLHYDROQUINONE

Determination of Carbonyl Compounds In Water by Dinitrophenylhydrazine Derivatization and HPLC/UV*

DOXYCYCLINE HYCLATE Final text to replace published monograph in The International Pharmacopoeia (November 2007)

Lonicera japonica Flower Dry Extract. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (

Identification and Determination Methods of Aspartame

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION

This method describes the identification of the following prohibited colorants in cosmetic products:

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

The Isosorbide Mononitrate Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

Lonicera japonica Flower Powder. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Appendix II- Bioanalytical Method Development and Validation

Chapter 4: Verification of compendial methods

IDENTIFICATION OF STEROIDS IN COSMETIC PRODUCTS BY TLC AND HPLC 1 02/12/2005 ACM 007 A. THIN LAYER CHROMATOGRAPHY (TLC)

Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets

Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page:

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT

Certificate of Analysis

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

USP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC

(RS)-2-(4-isobutyrylphenyl)propanoic acid Ibuprofen Impurity J

Certificate of Analysis

Certificate of Analysis

MEDROXYPROGESTERONE INJECTION

POLYDEXTROSES. SYNONYMS Modified polydextroses; INS No DEFINITION DESCRIPTION. FUNCTIONAL USES Bulking agent, humectant, stabilizer, thickener

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

Application Note. Author. Abstract. Xinlei Yang Agilent Technologies Co. Ltd Shanghai, China

12 Nicarbazin Nicarbazin (4,4 -dinitro carbanilid (DNC) and 2-hydroxy-4,6-dimethyl pyrimidine (HDP))

International Journal of Current Trends in Pharmaceutical Research. International Journal of Current Trends in Pharmaceutical Research

1-(2-METHOXYPHENYL)PIPERAZINE Latest revision: June 27, 2005

BENZYLPIPERAZINE Latest Revision: June 1, 2005

CHAPTER V ANALYTICAL METHODS ESTIMATION OF DICLOFENAC. Diclofenac (gift sample from M/s Micro Labs Ltd., Pondicherry)

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form

Ester Synthesis And Analysis: Aspirin and Oil of Wintergreen. Vanessa Jones November 19, 2015 Thursday 8:30 Lab Section Lab Partner: Melissa Blanco

Journal of Chemical and Pharmaceutical Research, 2017, 9(1): Research Article

GB Translated English of Chinese Standard: GB NATIONAL STANDARD OF THE

Change to read: PROCEDURE Buffer: 3.9 g/l of ammonium acetate in water. Adjust

What actually are dietary supplements? They are consumed in large quantities, but they

Certificate of Analysis

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

Intercontinental journal of pharmaceutical Investigations and Research

Chapter-4 EXPERIMENTAL WORK BY RP-HPLC

Dilution(*) Chromatography

Certificate of Analysis

Chemistry 3200 High Performance Liquid Chromatography: Quantitative Determination of Headache Tablets

ETHYL HYDROXYETHYL CELLULOSE

Development And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk

USP 35 Official Monographs / Azithromycin 2279 C 38H 72N 2O 12 H 2O

Simultaneous estimation of meclizine and nicotinic acid by using RP-HPLC

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105

Dissolution Test 2 was validated using an Inertsil ODS-3V brand of L1 column. The typical retention time for donepezil is about 5.5 min.

637. Thiamethoxam. HPLC method

Pelagia Research Library

Volume 6, Issue 2, January February 2011; Article-015

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

Determination of Caffeine by HPLC

Analysis of Metals, Halides, and Inorganic Ions Using Hydrophilic Interaction Chromatography

Department of Chemistry, JNTUACE, Kalikiri

Certificate of Analysis

LC Determination of Deferasirox in Pharmaceutical Formulation

2.1 2,3 Dichloro Benzoyl Cyanide (2,3 DCBC) and survey of. manufactured commonly for the bulk drug industry, few references were

International Journal of Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010

Saudi Journal of Medical and Pharmaceutical Sciences

Fast methods for the determination of ibuprofen in drug products

BRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Loss on drying Readily carbonizable substances

Transcription:

ADVANTAME SYNONYMS INS No. 969 Prepared at the 80 th JECFA (2015), published in FAO JECFA Monographs 17 (2015), superseding tentative specifications prepared at 77 th JECFA (2013). An ADI of 0-5 mg/kg body weight was established at the 77th JECFA (2013). DEFINITION Advantame is manufactured by N-alkylation of aspartic acid portion of aspartame (L-α-aspartyl-L-phenylalanine methylester) with 3-(3-hydroxy-4- methoxyphenyl) propionaldehyde produced by selective catalytic hydrogenation from 3-hydroxy-4-methoxycinnamaldehyde. The product is purified through re-crystallisation and dried. Only the following solvents may be used for the production: methanol and ethyl acetate. Chemical names (3S)-3-[3-(3-hydroxy-4-methoxyphenyl)propylamino]-4-[[(2S)-1-methoxy-1- oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid hydrate, N-[N-[3-(3- hydroxy-4-methoxyphenyl)propyl]-l-α-aspartyl]-l-phenylalanine 1-methyl ester, monohydrate C.A.S. number 714229-20-6 Chemical formula C 24 H 30 N 2 O 7 H 2 O Structural formula Formula weight 476.52 Assay DESCRIPTION FUNCTIONAL USES Not less than 97.0% and not more than 102.0% on the anhydrous basis White to yellow powder Sweetener, flavour enhancer CHARACTERISTICS IDENTIFICATION Solubility (Vol. 4) Very slightly soluble in water, sparingly soluble in ethanol

Infrared spectrum The infrared spectrum of a potassium bromide dispersion of the sample corresponds to the standard infrared spectrum in Appendix A. PURITY Water (Vol. 4) Residue on ignition (Vol. 4) Not more than 5% (Karl Fischer) Not more than 0.2% (use 5 g of the sample) N-[N-[3-(3-hydroxy-4- methoxyphenyl) propyl]- α-aspartyl]-l-phenylalanine (acid of advantame) Not more than 1% See description under TESTS Other related substances Not more than 1.5% (expressed as acid of advantame) See description under TESTS Specific rotation (Vol. 4) [α] D 20 : Between -46 and -39 (0.2% solution in ethanol, on an anhydrous basis) Residual solvents Methanol: Not more than 500 mg/kg Ethyl acetate: Not more than 500 mg/kg See description under TESTS Lead (Vol. 4) Not more than 1 mg/kg Determine using an AAS (Electrothermal atomization technique) appropriate to the specified level. The selection of sample size and method of sample preparation may be based on principles of methods described in Volume 4 (under General Methods, Metallic Impurities ). TESTS PURITY TESTS N-[N-[3-(3-hydroxy-4- methoxyphenyl) propyl]- α-aspartyl]-l-phenylalanine (acid of advantame) Principle Determination of N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]- L-phenylalanine by HPLC Mobile phase Mobile phase A: Dissolve 13.61 g of potassium dihydrogen phosphate in 1000 ml of water, and adjust the ph to 2.8 with phosphoric acid. Add 100 ml of acetonitrile to 900 ml of this solution, mix well, and sonicate for about 5 min. Mobile phase B: Dissolve 13.61 g of potassium dihydrogen phosphate in 1000 ml of water, and adjust the ph to 2.8 with phosphoric acid. Add 600 ml of acetonitrile to 400 ml of this solution, mix well, and sonicate for about 5 min. Standard solution Dissolve the acid of advantame reference standard (available from Wako Pure Chemicals, Osaka, Japan) in a mixture of water and acetonitrile (7:3 v/v) to concentrations of 15, 10, 5, 2 and 0.2 μg/ml. Preparation of Sample solution: Dissolve the sample in a mixture of water

and acetonitrile (7:3 v/v) to a concentration of 1 mg/ml. System suitability solution Prepare a solution containing 10 µg/ml of advantame reference standard and 10 µg/ml of acid of advantame reference standard (both available from Wako Pure Chemicals, Osaka, Japan) in a mixture of water and acetonitrile (7:3 v/v). HPLC conditions: Column: Column temperature: 50 Mobile phase: Mobile phase A: Inertsil ODS-2 (25 cm x 4.6 mm i.d., 5 µm), GL Sciences, or equiv. Mixture of phosphate buffer solution (ph 2.8) and acetonitrile (9:1 v/v) Mobile phase B: Mixture of phosphate buffer solution (ph 2.8) and acetonitrile (2:3 v/v) Flow rate: 1.0 ml/min Injection volume: 20 µl Detector: UV at 210 nm Run Time: 80 min Gradient program: Time (min) Mobile phase A (%) Mobile phase B (%) 0.0 85 15 30.0 85 15 55.0 75 25 75.0 0 100 80.0 0 100 80.1 85 15 90.0 85 15 System suitability requirement The resolution between the advantame and acid of advantame peaks is not less than 3.0 in the chromatogram of the System suitability solution. (Note: The approximate retention times for acid of advantame and advantame are 29.6 min and 56.0, respectively). Analysis Separately inject the Standard solution and the Sample solution into the chromatograph, record the chromatograms, and determine the peak area responses for the peaks in the resulting chromatograms. Calculation Calculate the percentage of acid of advantame in the sample using the following formula: Acid of advantame (%) = (r U /r S ) x (C S /C U ) x 100 where r U is the peak area response of advantame acid obtained from the chromatogram of the sample solution r S is the peak area response of advantame acid from the chromatogram of the standard solution C S is the concentration of the standard solution (µg/ml) C U is the concentration of the sample solution (µg/ml) See Appendix B for example of chromatogram obtained using the method.

Other related substances Calculation Calculate the total percentage of other related substances from the results of the Test for N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]-lphenylalanine using the following formula: Total content of other related substances (%) = (r T /r S ) x (C S /C U ) x 100 where r T is the total peak response of all peaks, except those of advantame and advantame acid obtained from the chromatogram of the sample solution (disregard any peak areas less than 0.02%) r S is the peak area response of advantame acid from the chromatogram of the standard solution C S is the concentration of the standard solution (µg/ml) C U is the concentration of the sample solution (µg/ml) Residual solvents Principle Proceed as directed in Residual Solvents by Headspace Gas Chromatography (Vol. 4) using the following: Sample solution Accurately weigh about 0.08 g of advantame to an appropriate headspace vial, and add 2 ml of DMF, apply the stopper, cap, and mix. Standard Solution Accurately weigh 0.1 g methanol, and add DMF to make exactly 10 ml (stock solution 1). Accurately weigh 0.1 g of ethyl acetate, and add DMF to make exactly 20 ml (stock solution 2). Transfer 1 ml of stock solution 1 and 1 ml of stock solution 2 into a 10-ml volumetric flask, and add DMF to make exactly 10 ml. Transfer 1 ml of this solution into a 10 ml volumetric flask, and add DMF to make exactly 10 ml (mixture stock solution). Transfer 1 ml of mixture stock solution into a 25 ml volumetric flask, and add DMF to make exactly 25ml. Transfer 2 ml of this solution to an appropriate headspace vial, apply the stopper, cap, and mix. Procedure Analyse using the analytical conditions for Residual Solvents by Headspace Gas Chromatography as described in Vol. 4. Calculation Calculate the content (mg/kg) of each residual solvent using the following formulae: where Content of methanol (mg/kg) = WSA / WT ATA / ASA 80 Content of ethyl acetate (mg/kg) = WSB / WT A TB / A SB 40 A TA is the peak area of methanol from the Sample solution; A TB is the peak area of ethyl acetate from the Sample solution ASA is the peak area of methanol from the Standard solution; ASB is the peak area of ethyl acetate from the Standard solution; WT is the weight (g) of Advantame in the Sample solution; WSA is the weight (g) of methanol in the Standard solution; and WSB is the weight (g) of ethyl acetate in the Standard solution.

METHOD OF ASSAY Principle Determine by HPLC using the following conditions: Mobile phase Mobile phase A: Dissolve 13.61 g of potassium dihydrogen phosphate in 1000 ml of water, and adjust the ph to 2.8 with phosphoric acid. Add 250 ml of acetonitrile to 750 ml of this solution, mix well, and sonicate for about 5 min. Mobile phase B: Dissolve 13.61 g of potassium dihydrogen phosphate in 1000 ml of water, and adjust the ph to 2.8 with phosphoric acid. Add 500 ml of acetonitrile to 500 ml of this solution, mix well, and sonicate for about 5 min. Iinternal standard Accurately weigh about 40 mg of benzoic acid and dissolve in a mixture of water and acetonitrile (7:3 v/v) to make exactly 50 ml. Standard stock solution Accurately weigh about 40 mg of advantame reference standard (available from Wako Pure Chemical Industries, Osaka, Japan), dissolve in a mixture of water and acetonitrile (7:3 v/v) to make 50 ml. Standard solution Pipet 8, 9 10, 11, 12 ml of standard stock solution into five volumetric flasks. Add 5 ml of the Internal standard solution to each volumetric flask, and add a mixture of water and acetonitrile (7:3 v/v) to make exactly 50 ml. Sample solution Accurately weigh about 40 mg of advantame and dissolve in a mixture of water and acetonitrile (7:3 v/v) to make exactly 50 ml. Pipet 10 ml of this solution, transfer into 50 ml volumetric flask, add exactly 5 ml of the internal standard solution, and add a mixture of water and acetonitrile (7:3 v/v) to make exactly 50 ml. HPLC conditions Column: Column temperature: 40 Mobile phase: Mobile phase A: Inertsil ODS-2 (25 cm x 4.6 mm i.d., 5 µm) GL Sciences, or equiv. Mixture of phosphate buffer solution (ph 2.8) and acetonitrile (75:25 v/v) Mobile phase B: Mixture of phosphate buffer solution (ph 2.8) and acetonitrile (50:50 v/v) Flow rate: 1.0 ml/min Injection volume: 20 µl Detector: UV at 280 nm Run Time: 55 min Gradient program: Time Mobile phase A Mobile phase B (min) (%) (%) 0 100 0 20 100 0 50 0 100 55 0 100

System suitability Suitability requirement 1: The resolution between the benzoic acid and advantame peaks is not less than 10 in the chromatogram of the standard solution having the concentration of advantame reference standard closest to 160 µg/ml. (Note: The elution order must be benzoic acid then advantame). Suitability requirement 2: When injected six consecutive times, the relative standard deviation for the retention time of the advantame peak is not more than 1.0% for the standard solution having the concentration of advantame reference standard closest to 160 µg/ml. Analysis Separately inject the Standard solutions into the chromatograph (including the stock solution), record the chromatograms, and determine the peak area responses for the major peaks in the resulting chromatographs (Note: The approximate retention time for advantame is 16.5 min). For each standard solution, calculate the ratio of the peak area response of the advantame peak to that of the benzoic acid internal standard peak. Create a standard curve by plotting the resulting peak area response ratios versus the concentrations of the standard solutions. Inject the Sample solution into the chromatograph, record the chromatogram, and determine the peak area responses for the major peaks in the resulting chromatogram. Calculate the ratio of the peak area response of the advantame peak to that of the benzoic acid internal standard peak. Using the standard curve, determine the concentration of advantame (C A ) in the sample solution, in µg/m. Calculation Calculate the percentage of advantame (C 24 H 30 N 2 O 7 ) in the sample taken: where Advantame (%) = (C A /C U ) x 100 C A is the concentration of advantame in the sample solution as determined from the standard curve (µg/ml) C U is the concentration of the sample solution (µg/ml) See Appendix C for example of chromatogram obtained using the method.

Appendix A IR spectrum of advantame standard (Ajinomoto Co., Inc.) Appendix B Representative chromatogram for advantame (ANS9801), N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]-l-phenylalanine (ANS9801-acid) and other related substances at 210 nm. Other identified compounds: L-α-aspartyl-L-phenylalanine methylester (Aspartame) N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]-l-phenylalanine (ANS9801-acid) N-[N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]-α-L-aspartyl]-α-L-aspartyl]-L-phenylalanine 1- methyl ester (N-Alkyl-AAPM) N-[N-[3-(3-hydroxy-4-methoxyphenyl)pentyl]-α-L-aspartyl]-L-phenylalanine 1-methyl ester (9801-D) N-[N-[3-(3-hydroxy-4-methoxyphenyl)heptyl]-α-L-aspartyl]-L-phenylalanine 1-methyl ester (9801-T)

Appendix C Representative chromatogram for Advantame using the Method of Assay at 280 nm